Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer

Protocol: OSU-16136

Full Title

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)


The purpose of this study is to determine whether nivolumab in combination with other

therapies is more effective than nivolumab alone in people with advanced lung cancer.

Are you eligible?

Inclusion Criteria:

Advanced Non Small Cell Lung Cancer (NSCLC)

Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 1

Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy


Must have at least 1 lesion with measurable disease

Exclusion Criteria:

Subjects with certain mutations that have not been treated with a targeted therapy

prior to enrollment

Subjects who need daily oxygen therapy

People with autoimmune disease